Who We Fund
Investments in Industry
- Agios
ABC2’s investment provided the support Agios needed to move its cancer metabolism project into brain cancer. Prior to our involvement, Agios focused exclusively on leukemia research.
- Exosome Diagnostics
ABC2 and Exosome Diagnostics are collaborating with two leading academic research centers to accelerate the clinical validation of Exosome Diagnostic's biofluid-based diagnostic technology.
- Genentech
ABC2 funded Genentech’s early stage research and clinical trial work to test and develop the drug Avastin to treat brain cancer patients.
- Regulus Therapeutics
Regulus is now working with Samsung Medical Center to develop a microRNA therapeutic to target the “master control switches” in brain tumors.
- Tocagen
ABC2 was the first non-profit organization to fund Tocagen, a biotech company that was able to then go onto raise an additional $85 million in private funding for their groundbreaking therapy.
- Duke Medicine
This collaboration establishes a missing link between the biopharmaceutical industry’s efforts to produce life-saving drugs and theoretical knowledge at the cutting edge of scientific inquiry.
Brain Tumor Research Grants
- Mayo Clinic / T-Gen
ABC2’s investment helps move forward a novel personalized medicine trial for glioblastoma patients led by Mayo Clinic, one of the leading clinical centers, and TGen, a cutting edge genomics lab.
- UCSF
Low grade gliomas tend to vary quite a bit, from a biological standpoint and how they respond to treatment.
- DIPG
ABC2’s investment and scientific guidance is helping to advance the work of an international consortium working on a treatment for a rare pediatric brain tumor called diffuse intrinsic pontine glioma (DIPG).
- Exosome Diagnostics
ABC2 and Exosome Diagnostics are collaborating with two leading academic research centers to accelerate the clinical validation of Exosome Diagnostic's biofluid-based diagnostic technology.
